Polaryx Therapeutics Stock Price, News & Analysis
Company Description
Polaryx Therapeutics (NASDAQ: PLYX) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $186.5M, ranking #4,695 among all listed U.S. companies by market cap.
PLYX stock has declined 89.7% over the past year. Shares last traded at $3.60.
On a trailing twelve-month basis, Polaryx Therapeutics reported net income of -$9.0M and diluted earnings per share of $-0.20.
This page provides a comprehensive overview of PLYX stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Polaryx Therapeutics (PLYX) stock last traded at $3.60, down 6.35% from the previous close. Over the past 12 months, the stock has lost 89.7%. At a market capitalization of $186.5M, PLYX is classified as a micro-cap stock with approximately 47.3M shares outstanding.
PLYX Rankings
Latest News
Polaryx Therapeutics has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 7 with negative movement. Key topics include clinical trial. View all PLYX news →
SEC Filings
Polaryx Therapeutics has filed 4 recent SEC filings, including 1 Form 4, 1 Form 10-Q, 1 Form 10-K, 1 Form SCHEDULE 13D. The most recent filing was submitted on May 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all PLYX SEC filings →
Financial Highlights
operating income reached -$7.8M, and net income was -$9.0M. Diluted earnings per share stood at $-0.20. The company generated -$3.9M in operating cash flow. With a current ratio of 8.55, the balance sheet reflects a strong liquidity position.
Upcoming Events
SOTERIA Phase 2 start
SOTERIA Phase 2 launch
Polaryx Therapeutics has 2 upcoming scheduled events. The next event, "SOTERIA Phase 2 start", is scheduled for July 1, 2026 (in 37 days). Investors can track these dates to stay informed about potential catalysts that may affect the PLYX stock price.
Short Interest History
Short interest in Polaryx Therapeutics (PLYX) currently stands at 237.7 thousand shares, down 39.6% from the previous reporting period, representing 0.5% of the float. Over the past 12 months, short interest has increased by 808.2%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Polaryx Therapeutics (PLYX) currently stands at 1.3 days, up 26% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has increased 26% over the past year, indicating either rising short interest or declining trading volume.
PLYX Company Profile & Sector Positioning
Polaryx Therapeutics (PLYX) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ. In monthly performance, the stock ranks #4,342 among all tracked companies.